165 related articles for article (PubMed ID: 20607308)
1. Risk factors for relapse of erosive GERD during long-term maintenance treatment with proton pump inhibitor: a prospective multicenter study in Japan.
Fujimoto K; Hongo M;
J Gastroenterol; 2010 Dec; 45(12):1193-200. PubMed ID: 20607308
[TBL] [Abstract][Full Text] [Related]
2. Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan.
Tominaga K; Iwakiri R; Fujimoto K; Fujiwara Y; Tanaka M; Shimoyama Y; Umegaki E; Higuchi K; Kusano M; Arakawa T;
J Gastroenterol; 2012 Mar; 47(3):284-92. PubMed ID: 22081052
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan.
Miwa H; Sasaki M; Furuta T; Koike T; Habu Y; Ito M; Fujiwara Y; Wada T; Nagahara A; Hongo M; Chiba T; Kinoshita Y;
Aliment Pharmacol Ther; 2007 Jul; 26(1):69-77. PubMed ID: 17555423
[TBL] [Abstract][Full Text] [Related]
4. Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors.
Sharma P; Johnson DA; Monyak JT; Illueca M
Aliment Pharmacol Ther; 2011 Aug; 34(4):487-93. PubMed ID: 21682754
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of long-term maintenance therapy with oral dose of rabeprazole 10 mg once daily in Japanese patients with reflux esophagitis.
Fujimoto K; Hongo M;
Intern Med; 2011; 50(3):179-88. PubMed ID: 21297318
[TBL] [Abstract][Full Text] [Related]
6. Incidence and risk factor of fundic gland polyp and hyperplastic polyp in long-term proton pump inhibitor therapy: a prospective study in Japan.
Hongo M; Fujimoto K;
J Gastroenterol; 2010 Jun; 45(6):618-24. PubMed ID: 20177714
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study.
Kinoshita Y; Kato M; Fujishiro M; Masuyama H; Nakata R; Abe H; Kumagai S; Fukushima Y; Okubo Y; Hojo S; Kusano M
J Gastroenterol; 2018 Jul; 53(7):834-844. PubMed ID: 29188387
[TBL] [Abstract][Full Text] [Related]
8. Gastroesophageal Reflux Disease in Time Covering Eradication for All Patients Infected with Helicobacter pylori in Japan.
Sugimoto M; Uotani T; Ichikawa H; Andoh A; Furuta T
Digestion; 2016; 93(1):24-31. PubMed ID: 26789391
[TBL] [Abstract][Full Text] [Related]
9. Increased esophageal mucosal/submucosal blood flow in patients with gastroesophageal reflux disease: normalization by treatment with a proton pump inhibitor.
Mine S; Iida T; Tabata T; Okada Y; Tanaka Y
J Gastroenterol Hepatol; 2008 Feb; 23(2):303-9. PubMed ID: 17725600
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors : Usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study.
Takeuchi T; Hongo H; Kimura T; Kojima Y; Harada S; Ota K; Takeuchi N; Noguchi T; Inoue T; Murano M; Higuchi K
J Gastroenterol; 2019 Nov; 54(11):972-983. PubMed ID: 31037449
[TBL] [Abstract][Full Text] [Related]
11. Examination on Factors Affecting Symptom Change after Drug Withdrawal in Patients with Mild Erosive Gastroesophageal Reflux Disease Undergoing Symptom-Controlled Maintenance Therapy with Acid-Secretion Inhibition Drugs.
Tanaka H; Takeuchi T; Nishida S; Hongo H; Takii M; Higashino T; Sanomura M; Miyazaki H; Hoshimoto M; Kimura T; Sakaguchi M; Abe T; Hakoda A; Sugawara N; Iwatsubo T; Kawaguchi S; Ota K; Kojima Y; Higuchi K
Digestion; 2023; 104(4):270-282. PubMed ID: 36649678
[TBL] [Abstract][Full Text] [Related]
12. Symptoms and quality of life in underweight gastroesophageal reflux disease patients and therapeutic responses to proton pump inhibitors.
Hongo M; Miwa H; Kusano M;
J Gastroenterol Hepatol; 2012 May; 27(5):913-8. PubMed ID: 22142515
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics of elderly patients with proton pump inhibitor-refractory non-erosive reflux disease from the G-PRIDE study who responded to rikkunshito.
Sakata Y; Tominaga K; Kato M; Takeda H; Shimoyama Y; Takeuchi T; Iwakiri R; Furuta K; Sakurai K; Odaka T; Kusunoki H; Nagahara A; Iwakiri K; Furuta T; Murakami K; Miwa H; Kinoshita Y; Haruma K; Takahashi S; Watanabe S; Higuchi K; Fujimoto K; Kusano M; Arakawa T;
BMC Gastroenterol; 2014 Jul; 14():116. PubMed ID: 24990161
[TBL] [Abstract][Full Text] [Related]
14. Influences of CYP2C19 polymorphism on recurrence of reflux esophagitis during proton pump inhibitor maintenance therapy.
Saitoh T; Otsuka H; Kawasaki T; Endo H; Iga D; Tomimatsu M; Fukushima Y; Katsube T; Ogawa K; Otsuka K
Hepatogastroenterology; 2009; 56(91-92):703-6. PubMed ID: 19621685
[TBL] [Abstract][Full Text] [Related]
15. Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease.
Lee YC; Lin JT; Wang HP; Chiu HM; Wu MS
J Gastroenterol Hepatol; 2007 Aug; 22(8):1286-92. PubMed ID: 17559380
[TBL] [Abstract][Full Text] [Related]
16. A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease.
Kobeissy AA; Hashash JG; Jamali FR; Skoury AM; Haddad R; El-Samad S; Ladki R; Aswad R; Soweid AM
World J Gastroenterol; 2012 May; 18(19):2390-5. PubMed ID: 22654431
[TBL] [Abstract][Full Text] [Related]
17. Eight weeks of esomeprazole therapy reduces symptom relapse, compared with 4 weeks, in patients with Los Angeles grade A or B erosive esophagitis.
Hsu PI; Lu CL; Wu DC; Kuo CH; Kao SS; Chang CC; Tai WC; Lai KH; Chen WC; Wang HM; Cheng JS; Tsai TJ; Chuah SK
Clin Gastroenterol Hepatol; 2015 May; 13(5):859-66.e1. PubMed ID: 25245625
[TBL] [Abstract][Full Text] [Related]
18. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group.
Thjodleifsson B; Beker JA; Dekkers C; Bjaaland T; Finnegan V; Humphries TJ
Dig Dis Sci; 2000 May; 45(5):845-53. PubMed ID: 10795744
[TBL] [Abstract][Full Text] [Related]
19. [Clinical aspects of gastroesophageal reflux disease in elderly patients: results of a 5-year prospective study].
Tsukanov VV; Onuchina EV; Vasyutin AV; Butorin NN; Amelchugova OS
Ter Arkh; 2014; 86(2):23-6. PubMed ID: 24772503
[TBL] [Abstract][Full Text] [Related]
20. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
Caro JJ; Salas M; Ward A
Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
